This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

PLC Systems’ RenalGuard® To Be Featured In Contrast-Induced Kidney Injury Session At TCT 2012

PLC Systems Inc. (OTCBB: PLCSF), a medical device company focused on innovative technologies for the cardiac and vascular markets, today announced that its lead product, RenalGuard ®, will be featured during Prevention of Contrast-Induced Kidney Injury: Focus on Hydration & New Frontiers , a 90-minute discussion session at Transcatheter Cardiovascular Therapeutics (TCT) 2012, being held October 22-26, 2012 at the Miami Beach Convention Center.

As part of its participation in this important conference, PLC will demonstrate RenalGuard in its booth (#805) and RenalGuard will also be displayed in the ACIST Medical Systems booth (#673) and in the Twins and Martin Equipment booth (#692) through Girlow USA. ACIST is PLC’s distributor in France and Germany, and Girlow is PLC's distributor in Latin and South America excluding Brazil.

Mark R. Tauscher, president and chief executive officer of PLC Systems, said, “We continue to see an increased focus worldwide on the issue of acute kidney injury caused by the use of contrast during imaging procedures, otherwise known as contrast-induced nephropathy (CIN). The development of CIN results in a range of serious and potentially deadly outcomes in patients who already have compromised kidney function, and clinical data continue to show that the use of RenalGuard and its associated therapy can reduce the incidence of this condition in at-risk patients.”

Mr. Tauscher continued, “This year’s TCT expects to attract a large international audience, which will provide us with increased exposure in countries where we are currently selling RenalGuard, including Latin America, South America and Europe. Current projections indicate that more than 60% of this year’s attendees will come from countries where RenalGuard is currently available through our network of distributors.”

Prevention of Contrast-Induced Kidney Injury: Focus on Hydration & New Frontiers is a 90-minute discussion of prevention techniques and therapies including RenalGuard and its associated matched fluid replacement therapy, and will include the principal investigators of the MYTHOS trial, Dr. Antonio Bartorelli, and the principal investigator of the REMEDIAL II trial, Dr. Carlo Briguori. Both trials demonstrated that patients treated with RenalGuard had a lower incidence rate of CIN compared with those treated with the current standard of care. It is one of a number of sessions related to CIN at this year’s conference, and takes place Friday, October 26, from 12:15 p.m. to 1:45 p.m. local time.

TCT is sponsored by the Cardiovascular Research Foundation, and more than 12,000 clinicians and professionals from around the world are expected to attend this year’s event.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs